Informações de Johnson & Johnson | Histórico, dados financeiros e desempenho de mercado

Mais detalhes de Johnson & Johnson Empresa

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.

Informações da empresa

Código da empresaJNJ

Nome da EmpresaJohnson & Johnson

Data de listagemSep 25, 1944

Fundado em1887

CEOMr. Joaquin Boix Duato

Número de funcionários138100

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 25

EndereçoOne Johnson & Johnson Plaza

CidadeNEW BRUNSWICK

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal08933

Telefone17325242455

Sitehttps://www.jnj.com/

Código da empresaJNJ

Data de listagemSep 25, 1944

Fundado em1887

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

276.91K

-32.09%

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

178.01K

+14.96%

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

94.62K

+14.54%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

84.95K

+4.05K%

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.59K

+18.96%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

15.54K

+6.62%

Ms. Kristen Mulholland

Chief Human Resource Officer, Executive Vice President

14.12K

+20.79%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

10.90K

+30.72%

Mrs. Anne M. Mulcahy

Independent Director

8.41K

+3.87%

Mr. Hubert Joly

Independent Director

5.00K

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

276.91K

-32.09%

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

178.01K

+14.96%

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

94.62K

+14.54%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

84.95K

+4.05K%

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.59K

+18.96%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

15.54K

+6.62%

Detalhamento da receita

Moeda: USDTempo de atualização: dom, 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Oncology-DARZALEX

11.67B

13.14%

Immunology-STELARA

10.36B

11.67%

Interventional Solutions

7.71B

8.68%

Surgery-General

5.36B

6.03%

Surgery-Advanced

4.49B

5.05%

Other

49.24B

55.43%

Por RegiãoUSD

Nome

Receita

Proporção

United States

50.30B

56.63%

International

38.52B

43.37%

Europe

20.21B

22.76%

Asia-Pacific, Africa

13.59B

15.30%

Western Hemisphere, excluding U.S.

4.71B

5.31%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Oncology-DARZALEX

11.67B

13.14%

Immunology-STELARA

10.36B

11.67%

Interventional Solutions

7.71B

8.68%

Surgery-General

5.36B

6.03%

Surgery-Advanced

4.49B

5.05%

Other

49.24B

55.43%

Acionista

Tempo de atualização: sex, 4 de abr

Estatísticas dos acionistas

Tipo

Estatísticas dos acionistas

Acionista

Proporção

The Vanguard Group, Inc.

9.63%

State Street Global Advisors (US)

5.59%

BlackRock Institutional Trust Company, N.A.

5.40%

Geode Capital Management, L.L.C.

2.40%

State Farm Insurance Companies

1.32%

Other

75.66%

Estatísticas dos acionistas

Acionista

Proporção

The Vanguard Group, Inc.

9.63%

State Street Global Advisors (US)

5.59%

BlackRock Institutional Trust Company, N.A.

5.40%

Geode Capital Management, L.L.C.

2.40%

State Farm Insurance Companies

1.32%

Other

75.66%

Tipo

Acionista

Proporção

Investment Advisor/Hedge Fund

33.44%

Investment Advisor

28.84%

Research Firm

2.91%

Pension Fund

2.29%

Bank and Trust

2.12%

Insurance Company

1.50%

Sovereign Wealth Fund

1.37%

Hedge Fund

0.75%

Foundation

0.36%

Other

26.42%

Participação acionária institucional

Tempo de atualização: qui, 20 de fev

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q1

5849

1.79B

74.14%

+9.00M

2024Q4

5953

1.78B

74.14%

+8.28M

2024Q3

5699

1.77B

73.47%

+2.69M

2024Q2

5691

1.75B

72.75%

+9.12M

2024Q1

5685

1.73B

71.58%

-6.08M

2023Q4

5686

1.72B

71.40%

-7.80M

2023Q3

5524

1.72B

71.21%

-159.24M

2023Q2

5528

1.87B

71.81%

+6.27M

2023Q1

5490

1.85B

71.21%

-28.44M

2022Q4

5447

1.87B

71.55%

+6.54M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

231.82M

9.62%

+1.80M

+0.78%

Dec 31, 2024

State Street Global Advisors (US)

134.46M

5.58%

+210.35K

+0.16%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

130.00M

5.39%

+2.12M

+1.65%

Dec 31, 2024

Geode Capital Management, L.L.C.

57.67M

2.39%

+1.56M

+2.78%

Dec 31, 2024

State Farm Insurance Companies

31.68M

1.31%

--

Dec 31, 2024

Norges Bank Investment Management (NBIM)

30.36M

1.26%

+1.26M

+4.34%

Dec 31, 2024

Wellington Management Company, LLP

24.36M

1.01%

+431.20K

+1.80%

Dec 31, 2024

JP Morgan Asset Management

24.04M

1%

+5.40M

+29.00%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

22.91M

0.95%

-654.88K

-2.78%

Dec 31, 2024

BlackRock Asset Management Ireland Limited

19.88M

0.82%

+587.38K

+3.05%

Dec 31, 2024

Ver Mais

ETFs Relacionados

Tempo de atualização: dom, 6 de abr

Nome

Proporção

iShares U.S. Pharmaceuticals ETF

21.89%

FT Vest DJIA Dogs 10 Target Income ETF

13.93%

First Trust NASDAQ Pharmaceuticals ETF

8.4%

American Century Focused Large Cap Value ETF

7.72%

Proshares Ultra Health Care

7.49%

Health Care Select Sector SPDR Fund

7.35%

iShares U.S. Healthcare ETF

7.23%

VanEck Pharmaceutical ETF

6.95%

JPMorgan Healthcare Leaders ETF

6.46%

Fidelity MSCI Health Care Index ETF

6.37%

Ver Mais

iShares U.S. Pharmaceuticals ETF

Proporção21.89%

FT Vest DJIA Dogs 10 Target Income ETF

Proporção13.93%

First Trust NASDAQ Pharmaceuticals ETF

Proporção8.4%

American Century Focused Large Cap Value ETF

Proporção7.72%

Proshares Ultra Health Care

Proporção7.49%

Health Care Select Sector SPDR Fund

Proporção7.35%

iShares U.S. Healthcare ETF

Proporção7.23%

VanEck Pharmaceutical ETF

Proporção6.95%

JPMorgan Healthcare Leaders ETF

Proporção6.46%

Fidelity MSCI Health Care Index ETF

Proporção6.37%

Dividendo

Um total de 56.79B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Jan 02, 2025

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025

Feb 18, 2025

Mar 04, 2025

Feb 18, 2025

Oct 15, 2024

JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024

Nov 26, 2024

Dec 10, 2024

Nov 26, 2024

Jul 17, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024

Aug 27, 2024

Sep 10, 2024

Aug 27, 2024

Apr 16, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024

May 21, 2024

Jun 04, 2024

May 20, 2024

Jan 02, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024

Feb 20, 2024

Mar 05, 2024

Feb 16, 2024

Oct 19, 2023

JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023

Nov 21, 2023

Dec 05, 2023

Nov 20, 2023

Jul 20, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023

Aug 28, 2023

Sep 07, 2023

Aug 25, 2023

Apr 18, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023

May 23, 2023

Jun 06, 2023

May 22, 2023

Jan 03, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023

Feb 21, 2023

Mar 07, 2023

Feb 17, 2023

Oct 18, 2022

JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022

Nov 22, 2022

Dec 06, 2022

Nov 21, 2022

Ver Mais

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

Johnson & Johnson

154.530USD

Johnson & Johnson

154.530

Visão Geral

Empresa